We defined hypermutated tumors as MSI-H tumors or those harboring POLE mutations that result in a dramatic TMB elevation, as there is robust evidence for MSI-H and POLE mutations as predictive biomarkers for a good response to immunotherapy in CRC (26, 27). The gene discussed is POLE; the disease is colorectal carcinoma.